Skip to main content

Table 2 Patient characteristics

From: Magnesium supplementation and high volume hydration reduce the renal toxicity caused by cisplatin-based chemotherapy in patients with lung cancer: a toxicity study

  High volume hydration Mg- High volume hydration Mg+ Low volume hydration Mg+
  (n = 41) (n = 27) (n = 17)
Age (year) 66 (63 to 70) 66 (57 to 70) 63 (62 to 67)
Gender Male (%) 31 (75.6) 18 (66.6) 16 (94.1)
BSA (m2) 1.7 ± 0.2 1.6 ± 0.2 1.7 ± 0.2
PS (ECOG): 0 (%) 5 (12.1) 4 (14.8) 5 (29.4)
    1 (%) 36 (87.8) 23 (85.2) 12 (70.6)
Stage  I (%) 0 (0) 1 (3.7) 0 (0)
    II (%) 5 (12.2) 3 (11.1) 3 (17.6)
    III (%) 25 (61.0) 15 (55.5) 8 (47.1)
    IV (%) 9 (22.0) 7 (25.9) 6 (35.3)
 Others (%) 2 (4.9) 1 (3.7) 0 (0)
Histology Adenocarcinoma (%) 17 (41.5) 13 (48.1) 11 (64.7)
    Squamous cell carcinoma (%) 11 (26.8) 7 (25.9) 5 (29.4)
    Small cell carcinoma (%) 9 (22.0) 6 (22.2) 1 (5.9)
    Others (%) 4 (9.8) 1 (3.7) 0 (0)
Serum Hb (g/dl) 13.3 (12.0 to 14.8) 13.6 (12.8 to 14.8) 13.3 (12.7 to 14.9)
Serum Alb (g/dl) 4.0 ± 0.4 4.1 ± 0.4 3.9 ± 0.4
Cisplatin dose (mg/m2) 80 (80 to 80) 80 (75 to 80) 80 (75 to 80)
Regular use drug    
NSAIDs (%) 10 (24.4) 2 (7.4) 2 (11.7)
Mg for purgative (%) 14 (34.1) 8 (29.6) 5 (29.4)
Combined anticancer agent (%)    
  VNB 22 (53.7) 13 (48.1) 10 (58.8)
  PEM 3 (7.3) 6 (22.2) 5 (29.4)
  CPT-11 3 (7.4) 1 (3.7) 0
  VP-16 8 (19.5) 6 (22.2) 1 (5.9)
  GEM 2 (4.9) 0 1 (5.9)
  S-1 1 (2.4) 1 (3.7) 0
  AMR 1 (2.4) 0 0
  DTX 1 (2.4) 0 0
  1. Continuous variables are expressed as mean ± standard deviation or median (interquartile range). Categorical variables are expressed as number (proportion).
  2. BSA, body surface area; PS, performance status; Hb, hemogulobin; Alb, albumin; NSAIDs, non-steroid anti-Inflammatory drugs; Non-Steroidal Anti-Inflammatory Drugs; Mg for purgative, Mg-contating medications for purgative; VNB, vinorelbine; PEM, pemetrexed; CPT-11, irinotecan; VP-16, etoposide; GEM, gemcitabine; AMR, amurubicin; DTX, docetaxel.